Cited 12 times in
Comparison of the response to treatment between Asian and Caucasian men with benign prostatic hyperplasia: long-term results from the combination of dutasteride and tamsulosin study
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 정병하 | - |
dc.contributor.author | 이승환 | - |
dc.date.accessioned | 2014-12-19T16:58:51Z | - |
dc.date.available | 2014-12-19T16:58:51Z | - |
dc.date.issued | 2012 | - |
dc.identifier.issn | 0919-8172 | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/90555 | - |
dc.description.abstract | The Combination of Avodart and Tamsulosin study was a 4-year, randomized, double-blind study of the efficacy and safety of dutasteride and tamsulosin, alone or in combination, in men with moderate-to-severe benign prostatic hyperplasia. In this post-hoc investigation, we analyzed primary and secondary end-points from the Combination of Avodart and Tamsulosin study in Asian (n = 325) and Caucasian men (n = 4259). The incidence of acute urinary retention or benign prostatic hyperplasia-related surgery did not differ significantly between treatment groups in the Asian subpopulation. In Caucasian men, the incidence of acute urinary retention/benign prostatic hyperplasia-related surgery was significantly lower in the combination therapy group compared with the tamsulosin monotherapy group (P < 0.001), but not compared with dutasteride monotherapy. Combination therapy significantly increased the time to benign prostatic hyperplasia clinical progression and resulted in improved International Prostate Symptom Score, maximum urinary flow rate, quality of life, and reduced prostate volume in Asian and Caucasian men who received combination therapy compared with tamsulosin monotherapy. Combination therapy also significantly improved (P < 0.05) time to benign prostatic hyperplasia clinical progression, International Prostate Symptom Score, maximum urinary flow rate and quality of life versus dutasteride in the Caucasian subpopulation. The adverse-event profile was comparable between subpopulations. In conclusion, Asian and Caucasian men respond similarly to these treatments, despite apparent racial differences in 5α-reductase activity. | - |
dc.description.statementOfResponsibility | open | - |
dc.relation.isPartOf | INTERNATIONAL JOURNAL OF UROLOGY | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.rights.uri | https://creativecommons.org/licenses/by-nc-nd/2.0/kr/ | - |
dc.subject.MESH | 5-alpha Reductase Inhibitors/administration & dosage | - |
dc.subject.MESH | 5-alpha Reductase Inhibitors/adverse effects | - |
dc.subject.MESH | 5-alpha Reductase Inhibitors/therapeutic use* | - |
dc.subject.MESH | Adrenergic alpha-1 Receptor Antagonists/administration & dosage | - |
dc.subject.MESH | Adrenergic alpha-1 Receptor Antagonists/adverse effects | - |
dc.subject.MESH | Adrenergic alpha-1 Receptor Antagonists/therapeutic use* | - |
dc.subject.MESH | Aged | - |
dc.subject.MESH | Antineoplastic Combined Chemotherapy Protocols/adverse effects | - |
dc.subject.MESH | Antineoplastic Combined Chemotherapy Protocols/therapeutic use* | - |
dc.subject.MESH | Asian Continental Ancestry Group | - |
dc.subject.MESH | Azasteroids/administration & dosage | - |
dc.subject.MESH | Azasteroids/adverse effects | - |
dc.subject.MESH | Azasteroids/therapeutic use* | - |
dc.subject.MESH | Double-Blind Method | - |
dc.subject.MESH | Dutasteride | - |
dc.subject.MESH | European Continental Ancestry Group | - |
dc.subject.MESH | Humans | - |
dc.subject.MESH | Male | - |
dc.subject.MESH | Middle Aged | - |
dc.subject.MESH | Prostatic Hyperplasia/drug therapy* | - |
dc.subject.MESH | Sulfonamides/administration & dosage | - |
dc.subject.MESH | Sulfonamides/adverse effects | - |
dc.subject.MESH | Sulfonamides/therapeutic use* | - |
dc.subject.MESH | Treatment Outcome | - |
dc.title | Comparison of the response to treatment between Asian and Caucasian men with benign prostatic hyperplasia: long-term results from the combination of dutasteride and tamsulosin study | - |
dc.type | Article | - |
dc.contributor.college | College of Medicine (의과대학) | - |
dc.contributor.department | Dept. of Urology (비뇨기과학) | - |
dc.contributor.googleauthor | Byung-Ha Chung | - |
dc.contributor.googleauthor | Seung Hwan Lee | - |
dc.contributor.googleauthor | Claus G Roehrborn | - |
dc.contributor.googleauthor | Paul F Siami | - |
dc.contributor.googleauthor | Kim Major-Walker | - |
dc.contributor.googleauthor | Timothy H Wilson | - |
dc.identifier.doi | 10.1111/j.1442-2042.2012.03091.x | - |
dc.admin.author | false | - |
dc.admin.mapping | false | - |
dc.contributor.localId | A02938 | - |
dc.contributor.localId | A03607 | - |
dc.relation.journalcode | J01169 | - |
dc.identifier.eissn | 1442-2042 | - |
dc.identifier.pmid | 22774774 | - |
dc.identifier.url | http://onlinelibrary.wiley.com/doi/10.1111/j.1442-2042.2012.03091.x/abstract | - |
dc.subject.keyword | 5-alpha Reductase Inhibitors/administration & dosage | - |
dc.subject.keyword | 5-alpha Reductase Inhibitors/adverse effects | - |
dc.subject.keyword | 5-alpha Reductase Inhibitors/therapeutic use* | - |
dc.subject.keyword | Adrenergic alpha-1 Receptor Antagonists/administration & dosage | - |
dc.subject.keyword | Adrenergic alpha-1 Receptor Antagonists/adverse effects | - |
dc.subject.keyword | Adrenergic alpha-1 Receptor Antagonists/therapeutic use* | - |
dc.subject.keyword | Aged | - |
dc.subject.keyword | Antineoplastic Combined Chemotherapy Protocols/adverse effects | - |
dc.subject.keyword | Antineoplastic Combined Chemotherapy Protocols/therapeutic use* | - |
dc.subject.keyword | Asian Continental Ancestry Group | - |
dc.subject.keyword | Azasteroids/administration & dosage | - |
dc.subject.keyword | Azasteroids/adverse effects | - |
dc.subject.keyword | Azasteroids/therapeutic use* | - |
dc.subject.keyword | Double-Blind Method | - |
dc.subject.keyword | Dutasteride | - |
dc.subject.keyword | European Continental Ancestry Group | - |
dc.subject.keyword | Humans | - |
dc.subject.keyword | Male | - |
dc.subject.keyword | Middle Aged | - |
dc.subject.keyword | Prostatic Hyperplasia/drug therapy* | - |
dc.subject.keyword | Sulfonamides/administration & dosage | - |
dc.subject.keyword | Sulfonamides/adverse effects | - |
dc.subject.keyword | Sulfonamides/therapeutic use* | - |
dc.subject.keyword | Treatment Outcome | - |
dc.contributor.alternativeName | Chung, Byung Ha | - |
dc.contributor.alternativeName | Lee, Seung Hwan | - |
dc.contributor.affiliatedAuthor | Lee, Seung Hwan | - |
dc.contributor.affiliatedAuthor | Chung, Byung Ha | - |
dc.citation.volume | 19 | - |
dc.citation.number | 11 | - |
dc.citation.startPage | 1031 | - |
dc.citation.endPage | 1035 | - |
dc.identifier.bibliographicCitation | INTERNATIONAL JOURNAL OF UROLOGY, Vol.19(11) : 1031-1035, 2012 | - |
dc.identifier.rimsid | 32831 | - |
dc.type.rims | ART | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.